β受体阻滞剂治疗射血分数保留性心衰的研究进展

霍礼超; 李梦丽; 乔成栋<sup>*</sup>

引用本文:	霍礼超,李梦丽,乔成栋.β受体阻滞剂治疗射血分数保留性心衰的研究进展[J].中国现代应用药学,2019,36(7):888-893.
	HUO Lichao,LI Mengli,QIAO Chengdong.Research Progress of β-Blockers in the Treatment of Heart Failure with Preserved Left Ventricular Ejection Fraction[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(7):888-893.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 1974次下载 1067次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
β受体阻滞剂治疗射血分数保留性心衰的研究进展
霍礼超¹, 李梦丽², 乔成栋¹
1.兰州大学第一医院老年病科, 兰州 730000;2.兰州大学第一医院肿瘤科, 兰州 730000

摘要:

射血分数保留性心衰已经成为心力衰竭的主要表现形式，占心力衰竭患者的近一半，而且随着现代诊疗技术的应用和人口预期寿命的延长，发病率呈上升趋势。目前，射血分数保留性心衰越来越受到人们的关注。β受体阻滞剂作为治疗心力衰竭的基础药物，在临床上的应用非常广泛。但其对于射血分数保留性心衰的应用效果还不理想。本文介绍了β受体阻滞剂治疗射血分数保留性心衰的机制以及现状，结合现有的临床证据，为今后的临床研究提供了方向。

关键词: 射血分数保留性心衰 β受体阻滞剂心力衰竭

DOI：10.13748/j.cnki.issn1007-7693.2019.07.024

分类号:R962

基金项目:

Research Progress of β-Blockers in the Treatment of Heart Failure with Preserved Left Ventricular Ejection Fraction

HUO Lichao¹, LI Mengli², QIAO Chengdong¹

1.The First Hospital of Lanzhou University, Department of Geriatrics, Lanzhou 730000, China;2.The First Hospital of Lanzhou University, Department of Oncology, Lanzhou 730000, China

Abstract:

The heart failure with preserved left ventricular ejection fraction(HFpEF) has become the main form of heart failure, nearly half of the population suffering from heart failure. With medical diagnosis and treatment technology widely used, and prolonged life expectancy, the incidence rate is increasing. At present, HFpEF is getting more and more attention. As a basic drug for heart failure, β-blockers are widely used in clinical practice. But it's use of HFpEF, the current results are not satisfactory. This article describes the mechanism and current status of β-blockers in the treatment of HFpEF. Combined with existing clinical evidence, it also provides direction for future clinical research.

Key words: heart failure with preserved left ventricular ejection fraction β-blockers heart failure